Browsing Category
Healthcare Industry News
2470 posts
Why Hester Biosciences’ trading window closure matters for investors chasing momentum in NSE: HESTERBIO
Hester Biosciences (NSE: HESTERBIO) has closed its trading window ahead of Q2 results. At ₹1,920 and 47x P/E, can the stock sustain its premium?
CurveBeam AI (ASX: CVB) stock trades near 9c placement price after A$6.5m raise
CurveBeam AI raises A$6.5m, launches vendor financing, and outlines China strategy. Find out how these moves could shift CVB’s stock and growth story today.
Can Nutex Health survive lawsuit claims over HaloMD ties, surprise billing reforms, and SEC delays?
Investors sue Nutex Health over arbitration revenue claims, accounting delays, and disclosure issues. Find out how this class action could impact NUTX stock.
MiraDx’s ASTRO 2025 breakthrough: Can PROSTOX ultra finally make radiation therapy safer for prostate cancer patients?
MiraDx’s PROSTOX ultra test at ASTRO 2025 shows high-risk prostate cancer patients can avoid SBRT toxicity with safer regimens. Read the full story.
NHS shifts procurement strategy: Can value-based medical technology investment reduce waiting lists?
NHS shifts procurement from cheapest-first to patient-first, investing in MedTech that improves care, reduces waiting lists, and delivers sustainable savings.
Medicare Advantage faces first enrollment decline in a decade—are UnitedHealth and Humana ready?
Medicare Advantage enrollment may fall by nearly 1 million in 2026. Find out why this shift matters for insurers, investors, and seniors.
DSM-Firmenich’s surprise move: Apollo gets a second shot as CVC falters in nutrition deal
DSM-Firmenich reopens its ANH auction as CVC’s bid falters, bringing Apollo back into play. Find out what this means for global nutrition M&A.
Can Zimmer Biomet’s new iodine-coated iTaperloc and iG7 systems change infection prevention in hip surgery?
Zimmer Biomet wins Japan approval for the world’s first iodine-treated hip implant, reshaping infection prevention in orthopedics.
Biolinq’s needle-free glucose monitor wins FDA nod — Could this disrupt Dexcom and Abbott’s CGM dominance?
Biolinq Shine earns FDA de novo clearance as the first needle-free CGM, challenging Dexcom and Abbott in the diabetes tech market.
Can Medline’s $5bn IPO revive Wall Street’s appetite for mega deals after years of delays?
Medline eyes a $5 B IPO by October in what could be 2025’s biggest listing. See how it impacts healthcare, private equity, and market sentiment.